OTC strep test?

Becton Dickinson acquires U.S. marketing rights to a dipstick strep test which could be an entry to the OCT market. The test, developed by Quidel of La Jolla, California, will initially be markedted in traditional fashion to MDs. An application to FDA's medical devices and diagnostics regulatory section is currently pending for an OTC version. B-D is also getting marketing rights to dipstick pregnancy and ovulation tests from Quidel. B-D is acquiring a less than 12% interest in Quidel.